# US 2025/0154239 A1 · Method for preventing or treating skin aging or inflammation or increasing a content of collagen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154239 A1
- Document ID: US20250154239A1
- Status: Published application
- Kind: A1
- Application number: 18/805,442
- Filed: 2024-08-14
- Published: 2025-05-15
- Earliest claimed: 2023-11-09
- Assignees: National Yang Ming Chiao Tung University; Taipei Veterans General Hospital
- Applicants: National Yang Ming Chiao Tung University; Taipei Veterans General Hospital
- Inventors: Ting-Ting CHANG; Jaw-Wen CHEN
- Web page: https://patentgrep.com/patent/US20250154239A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61Q 19/08: Anti-ageing preparations
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Provided is a method for treating or preventing skin aging or skin inflammation in an individual in need thereof, which includes administering an effective amount of a pharmaceutical composition to the individual. The pharmaceutical composition includes a CCL4 antagonist and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier thereof. Also provided is a method for increasing a content of collagen in an individual in need thereof, which includes administering an effective amount of a cosmetic composition to the individual.

## Claims

### Claim 1

A method for treating or preventing skin aging or skin inflammation in an individual in need thereof, which includes administering an effective amount of a pharmaceutical composition to the individual, and the pharmaceutical composition includes a CCL4 antagonist and/or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CCL4 antagonist is at least one selected from the group consisting of a CCL4 neutralizing antibody, a CCL4 RNAi agent, a CCL4 small molecule antagonist, a CCR1 antagonist, a CCR2 antagonist and a CCR5 antagonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein the skin aging includes skin laxity, dry skin, rough skin or slow wound healing.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition promotes angiogenesis, promotes wound healing, increases a content of collagen, reduces expression of an inflammatory factor, and/or reduces expression of an aging factor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is in a form for oral administration, intravenous injection, hypodermic injection, intradermic injection, intramuscular injection, intraperitoneal injection, or transdermal administration.

### Claim 6 (depends on 1)

The method of claim 1, wherein the CCL4 antagonist and/or the pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in an amount of 0.01 to 80 wt % based on a total weight of the pharmaceutical composition.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CCL4 antagonist and/or the pharmaceutically acceptable salt thereof is administered in an amount of 0.01 mg/kg to 100 mg/kg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered 1 to 25 times per week.

### Claim 9

A method for increasing a content of collagen in an individual in need thereof, which includes administering an effective amount of a cosmetic composition to the individual, and the cosmetic composition includes a CCL4 antagonist and/or a cosmetically acceptable salt thereof and a cosmetically acceptable carrier thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the CCL4 antagonist is at least one selected from the group consisting of a CCL4 neutralizing antibody, a CCL4 RNAi agent, a CCL4 small molecule antagonist, a CCR1 antagonist, a CCR2 antagonist, and a CCR5 antagonist.

### Claim 11 (depends on 9)

The method of claim 9, wherein the CCL4 antagonist and/or the cosmetically acceptable salt thereof is present in the cosmetic composition in an amount of 0.01 to 15 wt % based on the total weight of the cosmetic composition.
